Physician profile
Prabhat Sinha
NPI 1013988286
$12,231.83
in general payments reported to CMS, 2019-2025
62 companies · $1,607 in 2025
The $1,607 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,698 · 2020: $1,284 · 2021: $2,920 · 2022: $1,408 · 2023: $1,599 · 2024: $1,716 · 2025: $1,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,921.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,432.82 | 2020-2021 | |
| Abbvie INC. | $1,367.97 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $1,310.97 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,044.57 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $558.15 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $491.00 | 2019-2022 | |
| Corcept Therapeutics | $458.20 | 2023-2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $408.03 | 2021-2025 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $407.43 | 2021-2025 | |
| Amgen INC. | $402.20 | 2020-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $382.07 | 2019-2023 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $363.38 | 2019-2023 | Austedo Xr |
| Amarin Pharma, INC. | $293.71 | 2019-2020 | |
| Boston Scientific Corporation | $267.51 | 2019-2025 | General - Pain Management |
| Collegium Pharmaceutical, INC. | $266.75 | 2019-2022 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prabhat Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.